ARMR Sciences Targets Fentanyl as a Chemical Weapon | Immunogen Defense for First Responders
For investors, biotech innovators, and national-security analysts — this Fintech TV / New to The Street interview features Colin Gage, Co-Founder & CEO of ARMR Sciences, discussing how the company is developing biomedical countermeasures against the fentanyl epidemic — now being treated as a national-security chemical threat by U.S. authorities.
As fentanyl causes an estimated tens of thousands of American deaths annually, U.S. policy has increasingly shifted toward aggressive interdiction strategies. Reports of a classified DOJ memorandum further frame fentanyl as a potential chemical weapon, providing legal grounding for offshore smuggling vessel strikes.
ARMR Sciences addresses this crisis from a biomedical defense standpoint. Its preventative immunogen platform trains the immune system to neutralize fentanyl exposure before overdose or systemic reactions occur — with future development planned to cover emerging narcotics such as nitazenes and carfentanyl.
The technology is aimed squarely at protecting military and frontline responders — including DEA, FBI, Border Patrol, and Customs agents — who face the greatest exposure risks during interdiction operations. Gage likens the platform to a medical “bulletproof vest” for operatives engaged against narcotics trafficking networks.
As global synthetic drug threats evolve, ARMR Sciences’ mission centers on combining government enforcement actions with biotech immunity solutions, building what it hopes will become a sustainable public-private shield against the chemical warfare dimensions of modern drug trafficking.
#NewToTheStreet #ARMRSciences #Biotech #FentanylCrisis #ChemicalThreat #NationalSecurity #Immunogen #Biodefense #FirstResponders #PublicSafety #CounterNarcotics #SyntheticDrugs #DrugTerrorism #BiomedicalDefense #VeteransAndFirstResponders #HomelandSecurity #LawEnforcement #MedicalInnovation #BiotechInvesting #DefenseTechnology #PublicHealth #InvestorInsights
